Drugs / LY4174794
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07654972 | Jun 2026 → Apr 2029 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4174794 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07654972 ↗ |
| Route | Subcutaneous | “Participants will receive LY4174794 administered subcutaneously (SC).” NCT07654972 ↗ |